Researcher: Rystiggo approval a ‘step forward’ for gMG community
On June 27, Rystiggo became the first generalized myasthenia gravis (gMG) treatment to be approved by the U.S.
Articles by Lindsey Shapiro, PhD
Chinese authorities considering approval of efgartigimod for gMG
An under-the-skin formulation of efgartigimod is now being considered for approval in China for treating adults with generalized myasthenia…
Descartes-08, novel CAR T-cell therapy, shows promise in gMG
Descartes-08, an investigational RNA-based CAR T-cell therapy (rCAR-T), safely eased disease symptoms for up to nine months after treatment among…
FDA approves rozanolixizumab, known as Rystiggo, to treat gMG
The U.S. Food and Drug Administration (FDA) has approved rozanolixizumab, under the brand name Rystiggo, to treat adults with…
Subset of NK immune cells may promote MG autoimmunity: Study
A subset of immune cells called natural killer (NK) cells are elevated in the blood of myasthenia gravis (MG)…
AAN 2023: Ultomiris posts favorable clinical responses in trial analyses
More generalized myasthenia gravis (gMG) patients who received Ultomiris (ravulizumab) in the Phase 3 CHAMPION MG trial achieved…
Report: Rare case of seronegative MG precedes autoimmune encephalitis
A rare case of myasthenia gravis (MG) that preceded the onset of autoimmune encephalitis (AE) — a type of…
MDA 2023: Rozanolixizumab found to work in certain gMG patients
Treatment with rozanolixizumab — an investigational therapy being developed by UCB for generalized myasthenia gravis (gMG) — worked…
MDA 2023: Better effects found with Ultomiris within 2 years of diagnosis
The use of Ultomiris (ravulizumab) led to stronger reductions in generalized myasthenia gravis (gMG) symptoms for people who…
MDA 2023: Ultomiris eases gMG patients’ symptoms, slows worsening
Ultomiris (ravulizumab) treatment led to sustained reductions in generalized myasthenia gravis (gMG) symptom severity and acute clinical worsening…